These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31142846)

  • 21. Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.
    Malato A; Rossi E; Palumbo GA; Guglielmelli P; Pugliese N
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
    Björkholm M; Derolf AR; Hultcrantz M; Kristinsson SY; Ekstrand C; Goldin LR; Andreasson B; Birgegård G; Linder O; Malm C; Markevärn B; Nilsson L; Samuelsson J; Granath F; Landgren O
    J Clin Oncol; 2011 Jun; 29(17):2410-5. PubMed ID: 21537037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
    Björkholm M; Hultcrantz M; Derolf ÅR
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
    Tefferi A; Szuber N; Vallapureddy RR; Begna KH; Patnaik MM; Elliott MA; Christopher Hook C; Wolanskyj AP; Hanson CA; Ketterling RP; Pardanani A; Gangat N
    Am J Hematol; 2019 Jan; 94(1):5-9. PubMed ID: 30252953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
    Choi HS; Hong J; Hwang SM; Lee JH; Ma Y; Kim SA; Lee JY; Lee JO; Bang SM
    Ann Hematol; 2021 Oct; 100(10):2567-2574. PubMed ID: 34331110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
    Radaelli F; Onida F; Rossi FG; Zilioli VR; Colombi M; Usardi P; Calori R; Zanella A
    Hematology; 2008 Aug; 13(4):195-202. PubMed ID: 18796244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
    Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.
    Bjørn ME; Hasselbalch HC
    Expert Rev Hematol; 2017 May; 10(5):393-404. PubMed ID: 28402197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
    Stein BL; Gotlib J; Arcasoy M; Nguyen MH; Shah N; Moliterno A; Jamieson C; Pollyea DA; Scott B; Wadleigh M; Levine R; Komrokji R; Klisovic R; Gundabolu K; Kropf P; Wetzler M; Oh ST; Ribeiro R; Paschal R; Mohan S; Podoltsev N; Prchal J; Talpaz M; Snyder D; Verstovsek S; Mesa RA
    J Natl Compr Canc Netw; 2015 Apr; 13(4):424-34. PubMed ID: 25870379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of polycythaemia vera and essential thrombocythaemia.
    Tefferi A; Silverstein MN
    Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
    Mora B; Rumi E; Guglielmelli P; Barraco D; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Cavalloni C; Pietra D; Barbui T; Rotunno G; Cazzola M; Vannucchi AM; Giorgino T; Passamonti F
    Cancer Med; 2019 Aug; 8(9):4089-4092. PubMed ID: 31173472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
    Silver RT; Kiladjian JJ; Hasselbalch HC
    Expert Rev Hematol; 2013 Feb; 6(1):49-58. PubMed ID: 23373780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
    Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A
    Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
    Panova-Noeva M; Marchetti M; Buoro S; Russo L; Leuzzi A; Finazzi G; Rambaldi A; Ottomano C; Ten Cate H; Falanga A
    Blood; 2011 Sep; 118(9):2599-601. PubMed ID: 21750318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
    Griesshammer M; Sadjadian P
    Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
    Randi ML; Fabris F; Girolami A
    Leuk Lymphoma; 2000 Apr; 37(3-4):379-85. PubMed ID: 10752989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.